De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Khiron Life Sciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Onvoldoende gegevens om de gezondheid van Khiron Life Sciences te bepalen

Belangrijke informatie

n/a

Verhouding schuld/eigen vermogen

n/a

Schuld

Rente dekkingsratio	n/a
Contant	n/a
Aandelen	n/a
Totaal verplichtingen	n/a
Totaal activa	n/a

Recente financiële gezondheidsupdates

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

May 03

Recent updates

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 17

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now

Jun 24

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

May 03

What Type Of Returns Would Khiron Life Sciences'(CVE:KHRN) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 06

In dit gedeelte analyseren we gewoonlijk de financiële gezondheid van Khiron Life Sciences om te bepalen hoe goed het bedrijf is gepositioneerd in tijden van financiële nood, in het bijzonder het vermogen om de kasmiddelen en schulden te beheren. Khiron Life Sciences heeft geen adequate balansgegevens verstrekt, waardoor de financiële gezondheid niet goed kan worden beoordeeld.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door Simply Wall St wel financiële informatie hebben.

Analyse van de financiële positie

Kortlopende schulden: Er zijn onvoldoende gegevens om te bepalen of de kortetermijnactiva van KHRN.H de kortetermijnschulden dekken.

Langlopende schulden: Er zijn onvoldoende gegevens om te bepalen of de kortetermijnactiva van KHRN.H de langetermijnschulden dekken.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: Er zijn onvoldoende gegevens om de netto schuld/eigen vermogen ratio KHRN.H te berekenen om te bepalen of deze voldoende is.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van KHRN.H de afgelopen 5 jaar is gedaald.

Schuldendekking: Er zijn onvoldoende gegevens om te bepalen of de schulden van KHRN.H goed gedekt zijn door de operationele kasstroom.

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van KHRN.H op haar schulden goed worden gedekt door EBIT.

Khiron Life Sciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

Recent updates

Insufficient new directors

Insufficient new directors

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Khiron Life Sciences Corp. Announces Full Reimbursement by the NHS of Costs Associated to Cannabis-Based Medication and Clinic Fees for A Patient Enrolled in Zerenia Clinics UK

Third quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.019 loss in 3Q 2021)

Khiron Life Sciences Corp. to Report Q3, 2022 Results on Nov 30, 2022

Price target decreased to CA$0.30

Khiron Launches New Cannabis Products in Europe Including Stellar Genetics from California

Second quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.032 loss in 2Q 2021)

Khiron Life Sciences Corp. to Report Q2, 2022 Results on Aug 29, 2022

Khiron Life Sciences Corp. Announces CFO Changes

Khiron Life Sciences Corp. Announces Resignation of Deborah Rosati from the Board of Directors

Chairman of the Board recently bought CA$150k worth of stock

Khiron Life Sciences Corp. has completed a Composite Units Offering in the amount of CAD 4.01 million.

First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.036 loss in 1Q 2021)

Khiron Life Sciences Corp. (TSXV:KHRN) entered into an agreement to acquire Pharmadrug Production GmbH from Pharmadrug Inc. (CNSX:PHRX) for $1.82 Million.

Khiron Life Sciences Corp. to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings released: EPS: CA$0.20 (vs CA$0.20 loss in FY 2020)

Price target decreased to CA$0.87

Khiron Life Sciences Corp., Annual General Meeting, Jun 23, 2022

Khiron Life Sciences Corp. Publishes Clinical Study on the Effectiveness of its Products at Controlling Chronic Pain

No longer forecast to breakeven

Khiron Life Sciences Corp. (TSXV:KHRN) acquired Mcs Clinics Limited for 0.3 million.

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Khiron Life Sciences Corp. Presents Its First Research Study with 1,400 Patients

Second quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.049 loss in 2Q 2020)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now

Insider recently sold CA$78k worth of stock

First quarter 2021 earnings released: CA$0.036 loss per share (vs CA$0.079 loss in 1Q 2020)

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

Full year 2020 earnings released: CA$0.20 loss per share (vs CA$0.36 loss in FY 2019)

New 90-day high: CA$0.74

New 90-day high: CA$0.59

What Type Of Returns Would Khiron Life Sciences'(CVE:KHRN) Shareholders Have Earned If They Purchased Their SharesYear Ago?

New 90-day low: CA$0.36

Khiron Life Sciences Corp.'s Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia

Earnings beat expectations, revenue disappoints

Khiron Life Sciences Corp. Appoints Juan Carlos Echeverry to its Board of Directors

Third quarter 2020 earnings released: CA$0.057 loss per share

Khiron Life Sciences Corp. to Report Q3, 2020 Results on Dec 01, 2020

Khiron Life Sciences Corp. has completed a Composite Units Offering in the amount of CAD 12.6 million.

Earnings beat expectations, revenue disappoints

Second quarter 2020 earnings released: CA$0.049 loss per share

New 90-day low: CA$0.40

Khiron Life Sciences Corp. Announces Changes in Chief Financial Officer

New 90-day low: CA$0.45

Price target raised to CA$1.60

Earnings released

New 90-day low - CA$0.47

Khiron Life Sciences Corp. to Report Q2, 2020 Results on Aug 24, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven